ストックスクリーナーアプリを入手
7.94
3.52%
-0.29
アフターアワーズ：
7.91
-0.03
-0.38%
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
Number of shareholders of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
SPRY Should I Buy - Intellectia AI
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks - TipRanks
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript - Insider Monkey
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
ARS Pharmaceuticals gears up for Q1 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
ARS Pharma (SPRY) Q1 2026 Earnings Transcript - The Globe and Mail
Why (SPRY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) reports Q1 loss, beats revenue estimates - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program - MSN
Transcript : ARS Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 15, 2026 - marketscreener.com
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
ARS Pharma (SPRY) Q4 2025 Earnings Transcript - The Globe and Mail
ARS Pharmaceuticals 2026 Q1 10-Q: Financial Results, neffy™ Commercialization, and Key Risk Factors - Minichart
Rubric Capital (SPRY) reports 8.06% stake; 8,000,000 shares disclosed - Stock Titan
ARS Pharmaceuticals Q1 2026 Results: neffy® Drives $22.7M Revenue, U.S. and Global Expansion Updates - Minichart
ARS Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
SPRY: Q1 revenue hit $22.7M as neffy adoption surged, with expanded access set to drive further growth - TradingView
Earnings call transcript: ARS Pharmaceuticals misses Q1 2026 EPS forecast, stock drops - Investing.com
ARS Pharmaceuticals Delivers 185% Revenue Growth in Q1 2026 - AlphaStreet
ARS Pharmaceuticals earnings missed by $0.12, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss By Investing.com - Investing.com South Africa
ARS Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment - ChartMill
ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion - TipRanks
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell - Moomoo
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Investing News Network
ARS PHARMACEUTICALS ($SPRY) Releases Q1 2026 Earnings - Quiver Quantitative
ARS Pharmaceuticals 1Q 2026: Revenue $22.7M, EPS $(0.61) — 10-Q Summary - TradingView
Neffy launch drives ARS Pharmaceuticals (NASDAQ: SPRY) Q1 revenue jump - Stock Titan
ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss - Investing.com
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss - marketscreener.com
ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q1 Revenue $22.7M, vs. FactSet Est of $22.2M - marketscreener.com
ARS Pharmaceuticals (NASDAQ: SPRY) grows neffy sales but posts $60.6M Q1 loss - Stock Titan
Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Moomoo
ARS Pharmaceuticals Q1 2026 earnings preview - MSN
What's Driving ARS Pharmaceuticals' Q1 2026 Earnings Narrative - Kavout
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most A - Benzinga
ARS Pharmaceuticals Appoints Donn Casale as New President - The Globe and Mail
ARS Pharma names Donn Casale president - The Pharma Letter
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Sahm
ARS Pharmaceuticals appoints Donn Casale as president By Investing.com - Investing.com India
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):